Top

Published in:

01-11-2005 | Case Report

Treatment for HTLV-I associated arthropathy: a case study and synovial tissue culture analysis

Authors: Toshiaki Takahashi, Shigeki Takemoto, Katsuhito Kiyasu, Hiroshi Yamamoto, Toshikazu Tani, Isamu Miyoshi, Hirokuni Taguchi, Toshiaki Moriki, Emiko Miyazaki, Hideaki Enzan

Published in: Rheumatology International | Issue 1/2005

Abstract

Objective: There are few reports regarding the treatment of HTLV-I associated arthropathy (HAAP). This is a case study describing the treatment of a patient diagnosed with HAAP. We also analyzed the effects of various agents on cultured synovial tissue explants from the patient. Methods: Arthroscopic synovectomy of the left knee was performed. We investigated the effects of pirarubicin (THP), bestatin, betamethasone, and hyaluronic acid (HA) in synovial tissue culture to evaluate the efficacy of these medications. Results: Swelling and pain of the left knee was transiently diminished after synovectomy. However, bilateral swelling of the knees and C reactive protein (CRP) concentrations were increased. In the explant culture experiments, CD8+ cells decreased with the addition of bestatin, betamethasone, and HA. The structure of synovial cells was preserved by the addition of HA. However, the addition of THP induced fibrosis of synovial tissues, increased cells without nuclei, and diminished fascin-expressing cells. Conclusion: THP inhibited, but HA preserved the structure of hypertrophic synovial cells. Scopic synovectomy effectively improved joint effusion and pain; however, the effect was transient, and additional treatment with predonisolone was required. Therefore, it is important to develop a more effective treatment for HAAP.

Yoshida M, Miyoshi I, Hinuma Y (1982) Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 79:2031–2035PubMed

Osame MK, Usuku S, Izumo N, Ijichi H, Amitani A, Igata M, Matsumoto M, Tara M (1986) HTLV-I associated myelopathy, a new clinical entity. Lancet 1(8488):1031–1032CrossRef

Hirose S, Uemura Y, Fujishita M, Kitagawa T, Yamashita M, Imamura J, Ohtsuki Y, Taguchi H, Miyoshi I (1986) Isolation of HTLV-I from cerebrospinal fluid of a patient with myelopathy. Lancet 2(8503):397–398CrossRefPubMed

Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A, de The G (1985) Antibodies to human T-lymphotypic virus-type I in patients with tropical spastic paraparesis. Lancet 2(8452):407–410CrossRefPubMed

Taniguchi A, Takenaka Y, Noda Y, Ueno Y, Shichikawa K, Sato K, Miyasaka N, Nishioka K (1988) Adult T cell leukemia presenting with proliferative synovitis. Arthritis Rheum 31:1076–1077PubMed

Haynes BF, Miller SE, Palker TJ, Moore JO, Dunn PH, Bolognesi DP, Metzgar RS (1983) Identification of human T cell leukemia virus in a Japanease patient with adult T cell leukemia and cutaneous lymphomatous vasculitis. Proc Natl Acad Sci USA 80:2054–2058PubMed

Nishioka K, Maruyama I, Sato K. Kitajima I, Nakajima Y, Osame M (1989) Chronic inflammatory arthropathy associated with HTLV-I. Lancet 1(8635):441CrossRef

Aoyagi T, Maeda K, Furuichi I. Eguchi K, Sakai M, Nagataki S, Iwasaki K (1994) Treatment of patients with polyarthritis and anti-HTLV-I antibodies with interferon-alpha. Ann Rheum Dis 53:80–81PubMed

Arend WP, Dayer JM (1990) Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 33:305–315PubMed

10.

Sato K, Maruyama I, Maruyama Y, Kitajima I, Nakajima Y, Higaki M, Yamamoto K, Miyasaka N, Osame M, Nishioka K (1991) Arthritis in patients infected with human T lymphotropic virus type I. Clinical and immunopathologic features. Arthritis Rheum 34:714–721PubMed

11.

Nishiaka K, Sumida T, Hasunuma T (1996) Human T lymphotropic virus type I in arthropathy and autoimmune disorders. Arthritis Rheum 39:1410–1418PubMed

12.

Sagawa K, Mochizuki M, Masuoka K, Katagiri K, Katayama T, Maeda T, Tanimoto A, Sugita S, Watanabe T, Itoh K (1995) Immuno-pathological mechanisms of human T cell lymphotropic virus type 1 (HTLV-I) uveitis: detection of HTLV-I-infected T cells in the eye and their constitutive cytokine production. J Clin Invest 95:852–858PubMed

13.

Eguchi K, Matsuoka N, Ida H, Nakashima M, Sakai M, Sakito S, Kawakami A, Terada K, Shimada H, Kawabe Y (1992) Primary Sjogren’s syndrome with antibodies to HTLV-I: clinical and laboratory features. Ann Rheum Dis 51:769–776PubMed

14.

Sakai M, Eguchi K, Terada K, Nakashima M, Yamashita I, Ida H, Kawabe Y, Aoyagi T, Takino H, Nakamura T, Nagataki S (1993) Infection of human synovial cells by human T lymphotropic virus type I. J Clin Invest 92:1957–1966PubMed

15.

Uchiyama T, Hori T, Tsudo M, Wano Y, Umadome H, Tamori S, Yodoi J, Maeda M, Sawami H, Uchino H (1985) Interleukin-2-receptor (Tac antigen) expressed on adult T-cell leukemia cells. J Clin Invest 76:446–453PubMed

16.

Inoue J, Seiki M, Taniguchi T, Tsuru S, Yoshida M (1986) Induction of interleukin 2 receptor gene expression by p40^x encoded by human T-cell leukemia virus type 1. EMBO (Eur Mol Biol Organ) J 5:2883–2888

17.

Villinger PM, Cronin MT, Amenomori T, Wachsman W, Lotz M (1991). IL-6 production by human T lymphocytes expression in HTLV-I induced but not in normal T cells. J Immunol 146:550–559PubMed

18.

Fujisawa K, Asahara H, Okamoto K, Aono H, Hasunuma T, Kobata T, Iwakura Y, Yonehara S, Sumida T, Nishioka K (1996) Therapeutic effect of the anti-Fas antibody on arthritis in HTLV-I tax transgenic mice. J Clin Invest 98:271–278PubMed

Title: Treatment for HTLV-I associated arthropathy: a case study and synovial tissue culture analysis
Authors: Toshiaki Takahashi
Shigeki Takemoto
Katsuhito Kiyasu
Hiroshi Yamamoto
Toshikazu Tani
Isamu Miyoshi
Hirokuni Taguchi
Toshiaki Moriki
Emiko Miyazaki
Hideaki Enzan
Publication date: 01-11-2005
Publisher: Springer-Verlag
Published in: Rheumatology International / Issue 1/2005
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-005-0604-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2005

An unusual case of osteomalacia as the presenting feature of coeliac disease

Diabetes insipidus presentation before renal and pulmonary features in a patient with Wegener’s granulomatosis

The effects of carboxymethylated chitosan on metalloproteinase-1, −3 and tissue inhibitor of metalloproteinase-1 gene expression in cartilage of experimental osteoarthritis

Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment

The prevalence of autoantibodies against cartilage intermediate layer protein, YKL-39, osteopontin, and cyclic citrullinated peptide in patients with early-stage knee osteoarthritis: evidence of a variety of autoimmune processes

Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials